Status:
COMPLETED
Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma
Lead Sponsor:
Sanofi
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to define th Maximum Tolerated Dose (MTD) and the recommended dose (RD) of ZD6474 in combination with a fixed standard dose of gemcitabine and capecitabine
Eligibility Criteria
Inclusion
- Confirmed diagnosis of locally advanced unresectable or metastatic pancreatic adenocarcinoma
- ECOG performance status \<1
- Measurable disease
Exclusion
- Severe or uncontrolled systemic disease
- Clinically significant cardiac event such as myocardial infarction
- Any concomitant medication that may cause OTc prolongation, include Torsades de Pointes
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00681798
Start Date
July 1 2006
End Date
June 1 2009
Last Update
August 29 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Sankt Gallen, Canton of St. Gallen, Switzerland
2
Research Site
Bellinzona, Switzerland